Search
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414] … Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h.
Oxelumab
go.drugbank.com/drugs/DB16663InvestigationalOxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).
Bucelipase alfa
go.drugbank.com/drugs/DB16664InvestigationalBucelipase alfa is under investigation in clinical trial NCT00743483 (Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency).
Pimivalimab
go.drugbank.com/drugs/DB16667InvestigationalPimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After
Torudokimab
go.drugbank.com/drugs/DB16671InvestigationalTorudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).
Uliledlimab
go.drugbank.com/drugs/DB16675InvestigationalUliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).
Tegoprazan
go.drugbank.com/drugs/DB16690Investigational[A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. … Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.
Synonyms: K-CABCategories: Heterocyclic Compounds, 1-RingAxalimogene filolisbac
go.drugbank.com/drugs/DB16692InvestigationalAxalimogene filolisbac is under investigation in clinical trial NCT02853604 (Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer).
Insulin icodec
go.drugbank.com/drugs/DB16693ApprovedInvestigational[L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102] … Insulin icodec is an ultra long-acting basal insulin analogue.
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigationalPegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). … [A235000,A235005] Pegcetacoplan is a pegylated C3 inhibitor that can disrupt the processes leading to both forms of hemolysis that threaten patients with PNH.
Products: EMPAVELI® 54 MG/ML SOLUCIÓN INYECTABLE